BioSpecifics seeks to partner with companies that possess interesting new technologies and products in specialty markets. BioSpecifics contemplates entering into a range of creative deal structures that mutually benefit potential partners in their efforts to progress their scientific and business objectives.

We are currently partnered with Endo for CCH (marketed in the U.S. under the trade name XIAFLEX) and Endo continues to manage the research and development of XIAFLEX and CCH for their licensed indications.